New combo therapy aims to reawaken immune system against tough colon cancers
NCT ID NCT06557278
Summary
This study aimed to test whether a two-part experimental immunotherapy could help control advanced colorectal cancer that had stopped responding to all standard treatments. It was designed for patients whose cancer had spread and who had already tried and failed at least three prior lines of therapy. The approach combined an investigational drug called AlloStim with an approved immunotherapy (avelumab) to try to make the tumors more visible and vulnerable to the patient's own immune system.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hirschfield Oncology Center
Brooklyn, New York, 11206, United States
-
Mt. Sinai Comprehensive Cancer Center
Miami Beach, Florida, 33140, United States
-
New York Cancer and Blood Specialists
Shirley, New York, 11967, United States
Conditions
Explore the condition pages connected to this study.